APLS (Apellis Pharmaceuticals, Inc.) Bathi resik

Apellis Pharmaceuticals (APLS) relies on stable demand for ophthalmic drugs and strict temperature control during delivery. The company's net profit confirms this resilience, where 0.13 serves as the base parameter value. However, fierce patent battles and the risk of generic competitors force the business to constantly invest in new developments to maintain its competitive edge.

APLS (Apellis) riwayat Bathi resik saka 04.07.2022 nganti 30.05.2026

Rincian metrik keuangan lan pasar Apellis (APLS)

- rega lan prakiraan konsensus rega:

Kutipan saham Apellis Corp|APLS - Prakiraan konsensus analis

- indikator valuasi pasar bisnis:

Kapitalisasi pasar Apellis Corp|APLS - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- data kapitalisasi buku:

Nilai Akuntansi Saham Apellis Pharmaceuticals|APLS - Kapitalisasi Buku|Koefisien Nilai Pasar marang Nilai Buku apellis.com|APLS - Gunggung Aset Perusahaan

- informasi babagan utang lan solvabilitas:

Utang marang Modal Apellis Pharmaceuticals|APLS - Utang jangka dawa marang modal|Kewajiban jangka cendhak marang modal Apellis Pharmaceuticals, Inc.|APLS - Utang perusahaan|Utang-utang marang aset resik Apellis Corp|APLS - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Apellis Pharmaceuticals|Rasio likuiditas kritis apellis.com

- indikator pendapatan resik lan kelipatan nilai:

APLS - Bathi resik

Analisis dhasar perusahaan:APLS - Apellis Corp

Produk mawa merek Apellis Pharmaceuticals

This indicator reflects the aggregate market consensus regarding the daily net financial result, allowing for an assessment of operational efficiency through cleaned cash flow. By analyzing the profit dynamics of Apellis Pharmaceuticals (APLS), an investor can track the issuer's transition from costly R&D to the commercialization of ophthalmology drugs, where the smoothing of local volatility on the chart will signal long-term cash flow stabilization and a reduction in portfolio risks.

Pesaing langsung